Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vedolizumab Clear all
Completed Phase 2 Interventional Results available

Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT03138655
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis

NCT02611830
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Vedolizumab 300 mg IV, Placebo IV, Vedolizumab 108 mg SC, Placebo SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
28
States / cities
Little Rock, Arkansas • Wheat Ridge, Colorado • Middletown, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 16, 2026, 5:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

OTIS Vedolizumab Pregnancy Exposure Registry

NCT02678052
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn's Disease
Interventions
Vedolizumab, Other Biological Agent
Drug · Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 16, 2026, 5:26 PM EDT
Terminated Phase 4 Interventional Results available

Corticosteroids With Vedolizumab in Crohn's Disease

NCT02324699
View directory record Official record
Conditions
Crohn's Disease
Interventions
Prednisone, Placebo, Vedolizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 16, 2026, 5:26 PM EDT
Completed No phase listed Observational

Characterization of CD Responders to Vedolizumab

NCT04909359
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 16, 2026, 5:26 PM EDT
Terminated Phase 2 Interventional Results available

A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

NCT02993783
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
Vedolizumab
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 16, 2026, 5:26 PM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pilot Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Autoinjector (PFS+AI) in Healthy Participants

NCT03961295
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vedolizumab SC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 16, 2026, 5:26 PM EDT
Not listed No phase listed Observational

Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease

NCT05014555
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
GI Alliance
Other
Eligibility
18 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Jacksonville, Florida • Baton Rouge, Louisiana • Southlake, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Phase 1 Interventional Results available

Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption

NCT02788175
View directory record Official record
Conditions
HIV
Interventions
Entyvio (Vedolizumab)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 16, 2026, 5:26 PM EDT
Recruiting No phase listed Observational

High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy

NCT04331639
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis, Vitamin D Deficiency
Interventions
vitamin D3
Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
5 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Phase 4 Interventional

Determination of the Optimal Treatment Target in Ulcerative Colitis

NCT04259138
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C
Biological
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Withdrawn No phase listed Observational

A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease

NCT07250815
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
No intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients

NCT02461758
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD)
Interventions
Standard dose Influenza vaccine (SDIV), High dose influenza vaccine (HDIV)
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 64 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 16, 2026, 5:26 PM EDT
Completed No phase listed Observational

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness

NCT02423512
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 16, 2026, 5:26 PM EDT
Terminated No phase listed Observational

Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy

NCT03802214
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Vedolizumab
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Oct 16, 2026, 5:26 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Vedolizumab Induction May Prevent Celiac Enteritis

NCT02929316
View directory record Official record
Conditions
Celiac Disease
Interventions
Vedolizumab
Drug
Lead sponsor
AGA Clinical Research Associates, LLC
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Egg Harbor, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 16, 2026, 5:26 PM EDT
Recruiting No phase listed Observational

Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

NCT06750731
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
Interventions
Tappt
Device
Lead sponsor
Mercy Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
New Orleans, Louisiana • Chevy Chase, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

NCT02611817
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab SC 108 mg, Placebo, Vedolizumab IV 300 mg
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Phoenix, Arizona • Hamden, Connecticut • Middletown, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Phase 4 Interventional Results available

Defining Predictors of RT Response to Vedolizumab in IBD

NCT03142321
View directory record Official record
Conditions
Crohn Disease of Small Intestine
Interventions
Vedolizumab 300 MG Injection [Entyvio]
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease

NCT01224171
View directory record Official record
Conditions
Crohn's Disease
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
40
States / cities
Lafayette, Colorado • Hamden, Connecticut • Gainesville, Florida + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 16, 2026, 5:26 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

NCT02760615
View directory record Official record
Conditions
Colitis, Ulcerative, Crohn Disease
Interventions
Caffeine, Losartan, Omeprazole, Dextromethorphan, Midazolam, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
2
States / cities
Cypress, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 16, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

NCT03657160
View directory record Official record
Conditions
Hematopoietic Stem Cells
Interventions
Vedolizumab Placebo, Vedolizumab
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Oct 16, 2026, 5:26 PM EDT
Terminated Phase 3 Interventional Results available

Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC

NCT02954159
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Tacrolimus, Vedolizumab, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 16, 2026, 5:26 PM EDT